ADMA Biologics Inc (NASDAQ:ADMA) major shareholder Perceptive Advisors Llc purchased 4,563,700 shares of the stock in a transaction on Tuesday, February 11th. The shares were purchased at an average cost of $3.50 per share, with a total value of $15,972,950.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of ADMA opened at $3.58 on Thursday. The stock’s 50-day moving average is $4.06 and its two-hundred day moving average is $4.28. The stock has a market cap of $205.24 million, a PE ratio of -3.23 and a beta of 2.62. ADMA Biologics Inc has a 12 month low of $3.00 and a 12 month high of $6.31. The company has a debt-to-equity ratio of 2.33, a current ratio of 6.42 and a quick ratio of 3.76.
ADMA has been the topic of a number of recent research reports. ValuEngine upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating on shares of ADMA Biologics in a research note on Wednesday, January 8th. BidaskClub cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 29th. Finally, Maxim Group set a $12.00 price objective on ADMA Biologics and gave the stock a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.20.
Several institutional investors and hedge funds have recently modified their holdings of ADMA. Bank of New York Mellon Corp grew its stake in ADMA Biologics by 35.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 82,176 shares of the biotechnology company’s stock worth $317,000 after buying an additional 21,545 shares during the last quarter. Northern Trust Corp grew its stake in ADMA Biologics by 14.4% during the 2nd quarter. Northern Trust Corp now owns 299,248 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 37,677 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new position in ADMA Biologics during the 2nd quarter worth approximately $49,000. BlackRock Inc. grew its stake in ADMA Biologics by 94.0% during the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock worth $7,343,000 after buying an additional 919,260 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in ADMA Biologics by 47.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock worth $9,474,000 after buying an additional 786,567 shares during the last quarter. Institutional investors own 62.84% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Read More: How do candlesticks reflect price movement?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.